Analysis of the association of matrix metalloproteinase-1 gene promoter (rs1799750) polymorphism and risk of ovarian cancer

International Journal of Gynecological Cancer

Volumn 25, Issue 6, 2015, Pages 961-967

  Wang, Lijie ^a   Kong, Beihua ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Gene polymorphism; Matrix metalloproteinase 1; Meta analysis; Ovarian cancer

Indexed keywords

INTERSTITIAL COLLAGENASE; MMP1 PROTEIN, HUMAN;

ARTICLE; ASIAN; BLACK PERSON; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; QUALITY CONTROL; STATISTICAL SIGNIFICANCE; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; OVARY TUMOR; PROGNOSIS; RISK FACTOR;

CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MATRIX METALLOPROTEINASE 1; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK FACTORS;

EID: 84936937260     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000463     Document Type: Article

References (49)

1. Schuler S, Lattrich C, Skrzypczak M, et al. Icb-1 gene polymorphism rs1467465 is associated with susceptibility to ovarian cancer. J Ovarian Res. 2014; 7: 42.
2. Du JZ, Dong YL, Wan GX, et al. Lack of association between the COMT rs4680 polymorphism and ovarian cancer risk: evidence from a meta-analysis of 3, 940 individuals. Asian Pac J Cancer Prev. 2014; 15: 7941-7945.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
4. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998; 90: 1774-1786.
5. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010; 42: 410-414.
6. Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 2011; 43: 879-882.
7. Yin J, Lu K, Lin J, et al. Genetic variants in TGF-beta pathway are associated with ovarian cancer risk. PLoS One. 2011; 6: e25559.
8. Ma X, Zhang J, Liu S, et al. Polymorphisms in the CASP8 gene and the risk of epithelial ovarian cancer. Gynecol Oncol. 2011; 122: 554-559.
9. Permuth-Wey J, Kim D, Tsai YY, et al. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res. 2011; 71: 3896-3903.
10. Braem MG, Schouten LJ, Peeters PH, et al. Genetic susceptibility to sporadic ovarian cancer: a systematic review. Biochim Biophys Acta. 1816; 2011: 132-146.
11. Pelttari LM, Heikkinen T, Thompson D, et al. RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet. 2011; 20: 3278-3288.
12. Ramus SJ, Antoniou AC, Kuchenbaecker KB, et al. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat. 2012; 33: 690-702.
13. Bolton KL, Tyrer J, Song H, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010; 42: 880-884.
14. Goode EL, Chenevix-Trench G, Song H, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet. 2010; 42: 874-879.
15. Song H, Ramus SJ, Tyrer J, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet. 2009; 41: 996-1000.
16. Li Y, Zhao H, Sun L, et al. MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis. Hum Cell. 2011; 24: 57-64.
17. Li Y, Jin X, Kang S, et al. Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Gynecol Oncol. 2006; 101: 92-96.
18. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2: 161-174.
19. Orgaz JL, Pandya P, Dalmeida R, et al. Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. Nat Commun. 2014; 5: 4255.
20. Srivastava P, Kapoor R, Mittal RD. Impact of MMP-3 and TIMP-3 gene polymorphisms on prostate cancer susceptibility in North Indian cohort. Gene. 2013; 530: 273-277.
21. Slattery ML, John E, Torres-Mejia G, et al. Matrix metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer Health Disparities Study. PLoS One. 2013; 8: e63165.
22. Wieczorek E, Reszka E, Gromadzinska J, et al. Genetic polymorphism of matrix metalloproteinases in breast cancer. Neoplasma. 2012; 59: 237-247.
23. Sanli M, Akar E, Pehlivan S, et al. The relationship of metalloproteinase gene polymorphisms and lung cancer. J Surg Res. 2013; 183: 517-523.
24. Gonzalez-Arriaga P, Pascual T, Garcia-Alvarez A, et al. Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer. 2012; 12: 121.
25. Wieczorek E, Wasowicz W, Gromadzinska J, et al. Functional polymorphisms in the matrix metalloproteinase genes and their association with bladder cancer risk and recurrence: a mini-review. Int J Urol. 2014; 21: 744-752.
26. Wieczorek E, Reszka E, Wasowicz W, et al. MMP7 and MMP8 genetic polymorphisms in bladder cancer patients. Cent Eur J Urol. 2014; 66: 405-410.
27. Six L, Grimm C, Leodolter S, et al. A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer. Gynecol Oncol. 2006; 100: 506-510.
28. Kanamori Y, Matsushima M, Minaguchi T, et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res. 1999; 59: 4225-4227.
29. Biondi ML, Turri O, Leviti S, et al. MMP1 and MMP3 polymorphisms in promoter regions and cancer. Clin Chem. 2000; 46: 2023-2024.
30. Ju W, Kim JW, Park NH, et al. Matrix metalloproteinase-1 promoter polymorphism and epithelial ovarian cancer: does ethnicity matter?. J Obstet Gynaecol Res. 2007; 33: 155-160.
31. Wenham RM, Calingaert B, Ali S, et al. Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer. J Soc Gynecol Investig. 2003; 10: 381-7.
32. Yuan C, Wang C, Liu X, et al. Analyze association of the progesterone receptor gene polymorphism PROGINS with ovarian cancer risk. Mol Biol Rep. 2013; 40: 6001-6010.
33. Yuan C, Liu X, Yan S, et al. Analyzing association of the XRCC3 gene polymorphism with ovarian cancer risk. Biomed Res Int. 2014: 6481370.
34. Jiang DK, Wang WZ, Ren WH, et al. TP53 Arg72Pro polymorphism and skin cancer risk: a meta-analysis. J Invest Dermatol. 2011; 131: 220-228.
35. Shen SQ, Jiang DK, Liu GY, et al. Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk. Mol Biol Rep. 2012; 39: 4683-4690.
36. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22: 719-748.
37. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188.
38. Li Y, Wang Y, Kang S, et al. Association of single nucleotide polymorphism in matrix metalloproteinases promoter with susceptibility to ovarian cancer. Zhonghua Fu Chan Ke Za Zhi. 2005; 40: 472-475.
39. Zhu GD. Polymorphisms in the promoter regions of the matrix metalloproteinases-1, j3, j7, and j9 and the risk of epithelial ovarian cancer in China. Digest of the World Core Medical Journals (Obstetrics/Gynecology). 2006: 55.
40. Dey S, Ghosh N, Saha D, et al. Matrix metalloproteinase-1 (MMP-1) promoter polymorphisms are well linked with lower stomach tumor formation in eastern Indian population. PLoS One. 2014; 9: e88040.
41. Lukashev ME, Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 1998; 8: 437-441.
42. Vincenti MP, White LA, Schroen DJ, et al. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot Gene Expr. 1996; 6: 391-411.
43. Pulukuri SM, Rao JS. Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int J Oncol. 2008; 32: 757-765.
44. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997; 89: 1260-1270.
45. Hewitt RE, Leach IH, Powe DG, et al. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer. 1991; 49: 666-672.
46. Baker EA, Leaper DJ. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J Cancer. 2003; 39: 981-988.
47. Murray GI, Duncan ME, Arbuckle E, et al. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut. 1998; 43: 791-797.
48. Murray GI, Duncan ME, O'Neil P, et al. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol. 1998; 185: 256-261.
49. Srivastava P, Gangwar R, Kapoor R, Mittal RD. Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population. Dis Markers. 2010; 29: 37-46